NANOBIOTIX
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
Filed with Euronext ·
Watch Nanobiotix's latest callNanobiotix (Euronext:NANO) Q4 2025 Earnings Call · Replay · Apr 1Read the transcript of Nanobiotix (Euronext:NANO) Q4 2025 Earnings Call6ix is reading this filing.
View original source (GlobeNewswire)Nanobiotix SA on 6ix
Story so far
- Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
- Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
- NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Earlier from Nanobiotix
- Voting Rights and Shares Capital of the Company
- NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
- NANOBIOTIX annonce la nomination d’Arnd Christ au poste de directeur financier
- NANOBIOTIX Provides First Half 2026 Operational and Financial Update
- NANOBIOTIX fait le point sur ses activités et ses résultats financiers du premier semestre 2026
Follow Nanobiotix into a list and get an email when it puts out news.
Follow Nanobiotix